{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:35:30Z","timestamp":1790253330516,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bulcan.2018.10.005","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:47:15Z","timestamp":1542674835000},"page":"1126-1134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Administration de trastuzumab par voie sous-cutan\u00e9e \u00e0 domicile\u00a0: retour d\u2019exp\u00e9rience des patientes trait\u00e9es en 2016\u00a0par l\u2019hospitalisation \u00e0 domicile Sant\u00e9 Service"],"prefix":"10.1016","volume":"105","author":[{"given":"Christine","family":"Pailler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Chapot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Softa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gandrille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvaine","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.10.005_bib0090","series-title":"Projection de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine en 2015","author":"Leone","year":"2015"},{"issue":"16","key":"10.1016\/j.bulcan.2018.10.005_bib0095","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2018.10.005_bib0100","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2018.10.005_bib0105","unstructured":"CT-13363_HERCEPTIN_PIC_INS_Avis2_CT13363.pdf [Internet]. [cit\u00e9 9\u00a0nov 2017]. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-13363_HERCEPTIN_PIC_INS_Avis2_CT13363.pdf."},{"issue":"10","key":"10.1016\/j.bulcan.2018.10.005_bib0110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2018.10.005_bib0115","first-page":"51","article-title":"The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home","volume":"9","author":"Tjalma","year":"2017","journal-title":"Facts Views Vis ObGyn"},{"issue":"3","key":"10.1016\/j.bulcan.2018.10.005_bib0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bulcan.2015.01.007","article-title":"Herceptin\u00ae (trastuzumab) par voie sous-cutan\u00e9e\u00a0: une mini r\u00e9volution\u00a0? \u00c9tude pharmaco-\u00e9conomique","volume":"102","author":"Lieutenant","year":"2015","journal-title":"Bull Cancer (Paris)"},{"issue":"01","key":"10.1016\/j.bulcan.2018.10.005_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/abcr.2016.51001","article-title":"Economic analysis of intravenous vs. subcutaneously administered trastuzumab for the treatment of HER2+ early breast cancer in Malaysia","volume":"05","author":"Lee","year":"2016","journal-title":"Adv Breast Cancer Res"},{"key":"10.1016\/j.bulcan.2018.10.005_bib0130","unstructured":"Synthese-plan-cancer2014.pdf [Internet]. [cit\u00e9 13\u00a0oct 2017]. Disponible sur\u00a0: http:\/\/www.had-relais-sante.fr\/fichier\/actualites\/Synthese-plan-cancer2014.pdf."},{"key":"10.1016\/j.bulcan.2018.10.005_bib0135","unstructured":"Chimio_synth.pdf [Internet]. [cit\u00e9 9\u00a0oct 2017]. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/Chimio_synth.pdf."},{"key":"10.1016\/j.bulcan.2018.10.005_bib0140","unstructured":"conditions_du_developpement_de_la_chimiotherapie_en_hospitalisation_a_domicile_-_rapport.pdf [Internet]. [cit\u00e9 9\u00a0oct 2017]. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015-03\/conditions_du_developpement_de_la_chimiotherapie_en_hospitalisation_a_domicile_-_rapport.pdf."},{"issue":"2","key":"10.1016\/j.bulcan.2018.10.005_bib0145","first-page":"71","article-title":"\u00c9volution des bioth\u00e9rapies dans le cancer du sein","volume":"15","author":"Bos","year":"2015","journal-title":"Bull Infirm Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2018.10.005_bib0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1684\/bdc.2010.1170","article-title":"Quality insurance system establishment in the management of home-based chemotherapy: example of hospital at home \u201cAssistance publique-H\u00f4pitaux de Paris\u201d","volume":"97","author":"Benizri","year":"2010","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2018.10.005_bib0155","author":"Leca","year":"2017","journal-title":"Trastuzumab par voie sous-cutan\u00e9e\u00a0: quels impacts en pratique ? Sciences pharmaceutiques"},{"issue":"4\u00a0Supplement","key":"10.1016\/j.bulcan.2018.10.005_bib0160","article-title":"Abstract P4-21-17: BELIS: safety and tolerability of at home administration of trastuzumab (Herceptin\u00ae) subcutaneous for the treatment of patients with HER2-positive early breast cancer","volume":"77","author":"Cocquyt","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2018.10.005_bib0165","series-title":"Conditions du d\u00e9veloppement de la chimioth\u00e9rpaie en hospitalisation \u00e0 domicile\u00a0: analyse \u00e9conomique et organisationnelle. Service \u00e9valuation \u00e9conomique et sant\u00e9 publique HAS","year":"2015"},{"issue":"3\u00a0Pt 1","key":"10.1016\/j.bulcan.2018.10.005_bib0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0761-8425(06)71575-3","article-title":"Analyse \u00e9conomique de l\u2019administration d\u2019une chimioth\u00e9rapie en hospitalisation \u00e0 domicile (HAD) compar\u00e9e \u00e0 l\u2019hospitalisation de jour dans les cancers bronchopulmonaires non \u00e0 petites cellules de stade IV","volume":"23","author":"Vergnen\u00e8gre","year":"2006","journal-title":"Rev Mal Respir"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T15:14:11Z","timestamp":1605453251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118303114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0007455118303114"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.10.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration de trastuzumab par voie sous-cutan\u00e9e \u00e0 domicile\u00a0: retour d\u2019exp\u00e9rience des patientes trait\u00e9es en 2016\u00a0par l\u2019hospitalisation \u00e0 domicile Sant\u00e9 Service","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}